ClinicalTrials.gg
CompletedNCT04230499Updated Oct 22, 2026Results posted

Trial of eRapa to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active Surveillance

A Phase 2 interventional study of Encapsulated Rapamycin (eRapa) in Familial Adenomatous Polyposis, sponsored by Rapamycin Holdings Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Rapamycin Holdings Inc. · Phase 2, Interventional, and Treatment

Updated Oct 22, 2026Now CompletedResults posted+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies in Adenomatous Polyposis Coli with a site in United States — 12 open to participants now, 12 under way, 1 of them phase 3. Adenomatous Polyposis Coli · United States.

Enrollment
21st of 27
30 · median 42
Started
2021
with 3 others
Phase 2
8 of 39
1 open now
Registered
25th of 39
by date
Lead sponsor
2 of 39
Rapamycin Holdings Inc.

Among the 39 studies in Adenomatous Polyposis Coli with a site in United States, this one is the 21st largest by enrollment of the 27 interventional ones that give a count, is one of 4 that started in 2021, is one of 8 in phase 2, and was the 25th registered.

Adenomatous Polyposis Coli

92 studies on the registry are indexed under Adenomatous Polyposis Coli; 28 are open to participants now.

Browse Adenomatous Polyposis Coli studies →

Open to participants now

12 of the 39 studies in Adenomatous Polyposis Coli with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 20 Adenomatous Polyposis Coli studies recruiting now, 15 (75%) set no upper age limit and 2 (10%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Adenomatous Polyposis Coli with a site in United States, or all of them as a file.
02

Study summary

Patients with Familial Adenomatous Polyposis (FAP) who are undergoing endoscopic surveillance will be given Encapsulated Rapamycin (eRapa) at one of three escalating doses/schedules for 12 months with the aim of reducing polyp burden.

Read the detailed description

Patients with FAP who are undergoing endoscopic surveillance will be given eRapa at one of three escalating doses/ schedules (0.5mg every other day, 0.5mg daily every other week, or 0.5mg daily) for 12 months with the aim of reducing polyp burden. Patients will serve as their own controls. Patients will be assessed with surveillance endoscopy at baseline, 6 months, and 12 months for change in polyp burden. Correlation between immune markers and clinical outcomes will be explored.

This is a Phase IIa trial which will enroll at approximately 6-8 sites within the United States that have specialty expertise in FAP treatment and surveillance. The trial is anticipated to last approximately 24 months for treatment and follow up.

The trial will enroll 30 patients with the genetic or clinical diagnosis of FAP. The clinical diagnosis includes individuals with 100 or more cumulative tubular adenomas throughout the colorectum. Patients must be undergoing surveillance for known FAP and can include those with intact colons as well as those who have undergone surgical therapy. For those patients who have undergone partial or total colectomy, they must have documented residual polyps in their rectum for which they are receiving active surveillance.

Once the recommended phase 2 dose (RP2D) is identified, subjects will undergo evaluation under fed and fasted states to determine the food effect on eRapa absorption.

03

Conditions studied

  • Familial Adenomatous Polyposis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Sign and date an form.
  2. Stated willingness to comply with all study procedures and availability for the duration of the study.
  3. Male or female, age at least 18 years at the time of consent.
  4. Phenotypic familial adenomatous polyposis (FAP) with disease involvement of the colorectum by either genetic or clinical diagnosis: Adenomatous polyposis coli (APC) germline mutation with or without family history, or with greater than a cumulative lifetime history of (>) 100 adenomas in large intestine and a family history of FAP, or FAP phenotype post colectomy for polyposis with a family history of FAP. Minimum number of polyps required for enrollment is 10.
  5. Abilitiy to safely undergo endoscopy.
  6. Ability to take oral medication and be willing to adhere to the eRapa regimen.
  7. For females of : use of highly effective for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 12 weeks after the end of eRapa administration.
  8. A woman must agree not to breast feed or donate eggs (ova, oocytes) during the study and for a period of 12 weeks after the last administration of study drug.

Exclusion criteria

Exclusion Criteria:

  1. Risk-reduction surgery (colectomy or partial colectomy) within the 12 months prior to screening.
  2. Use of non-steroidal anti-inflammatory drugs other than aspirin during the study. The use of 81 milligrams (mg) of aspirin a day or 650 mg of aspirin per week is allowed.
  3. Treatment with other FAP-directed drug therapy (including NSAID [Non-steroidal anti-inflammatory drug] drugs), unless completes a 4 week prior to enrollment.
  4. Duodenum or colon/ rectum with high grade dysplasia or cancer on at screening.
  5. Duodenal or colorectal polyp > 1 centimeter (cm) not excised at the screening evaluation.
  6. Pregnancy or breast feeding.
  7. Unable to provide consent or anticipated inability to attend appropriate follow-up visits.
  8. Serum creatinine or measured/ calculated (or [GFR]) > 1.5 x OR \< 30mL/min for participants with creatine levels > 1.5 x institutional ULN. ≥ 1.5 x ULN unless conjugated bilirubin ≤ ULN; alkaline phosphatase > 5 x ULN; /AST > 2 x ULN.
  9. or PT or aPTT > 1.5 x institutional ULN unless the patient is receiving anticoagulant therapy as long as the PT or aPTT is within therapeutic range of intended use of anticoagulants.
  10. Proteinuria > 1+ on urinalysis or > 1g/24h on 24h urine.
  11. History of interstitial lung disease or non-infectious pneumonitis.
  12. state (e.g., , use of chronic ), active, uncontrolled infection.
  13. On agents known to alter rapamycin metabolism significantly.
  14. Concurrent involvement in other clinical trials specifically evaluating chemoprevention in FAP.
  15. Patients with a colonic polyp burden too numerous to count.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Cohort 1 will receive 0.5mg of eRapa every other day.

    Drug: Encapsulated Rapamycin (eRapa)

  • Experimental
    Cohort 2

    Cohort 2 will receive 0.5mg of eRapa daily with 7 days on therapy, followed by 7 days off therapy.

    Drug: Encapsulated Rapamycin (eRapa)

  • Experimental
    Cohort 3

    Cohort 3 will receive 0.5 mg of eRapa daily.

    Drug: Encapsulated Rapamycin (eRapa)

  • Experimental
    Food Effect

    Upon identification of the RP2D, after a 2 week washout (14 days), subjects will be randomized into a fed and fasted (2 weeks - 14 days) two period cross over, with an intervening 2 week washout (14 days) for a total of 2 months (8 weeks).

    Drug: Encapsulated Rapamycin (eRapa)

Interventions

  • eRapa is encapsulated rapamycin. The rapamycin is encapsulated in order to deliver the rapamycin at a consistent and lower dosage. eRapa is a capsule, and is administered orally.

    Also known as: eRapa; Encapsulated sirolimus

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Colorectal Polyp Burden at Month 6

    Colorectal polyp burden was assessed by colonoscopy at baseline and Month 6 (180 days), performed by the same gastroenterologist whenever possible. Polyps measuring ≥3 mm were counted, and the diameter of each eligible polyp was measured. Colorectal polyp burden was defined as the sum of the diameters of all eligible colorectal polyps. Polyps removed at the baseline endoscopy were excluded from the baseline polyp burden calculation to avoid attributing reductions due to polypectomy to study treatment. Percent change from baseline was calculated as: (Month6polypburden-adjustedbaselinepolypburden)÷adjustedbaselinepolypburden × 100.

    Time frame: 6 months

Secondary outcomes

  1. Percent Change From Baseline in Colorectal Polyp Burden at Month 12

    Colorectal polyp burden was assessed by colonoscopy at baseline and Month 12 (360 days), performed by the same gastroenterologist whenever possible. Polyps measuring ≥3 mm were counted, and the diameter of each eligible polyp was measured. Colorectal polyp burden was defined as the sum of the diameters of all eligible colorectal polyps. Polyps removed at the baseline endoscopy were excluded from the baseline polyp burden calculation to avoid attributing reductions due to polypectomy to study treatment. Percent change from baseline was calculated as: \[(Month 12 polyp burden - adjusted baseline polyp burden) ÷ adjusted baseline polyp burden\] × 100.

    Time frame: 12 months.

  2. Clinical Effect of eRapa on International Society for Gastrointestinal Hereditary Tumors (InSiGHT) Stage.

    The International Society for Gastrointestinal Hereditary Tumours (InSiGHT) Familial Adenomatous Polyposis (FAP) Staging System is a validated clinical scoring system used to assess the severity of polyposis in patients with FAP. Staging is based on polyp number, size, endoscopic resectability, and the presence of advanced pathology. The scale consists of a single overall stage (0-4) and does not include subscale scores: Stage 0 = 0-10 polyps, all \<5 mm; Stage 1 = 10-25 polyps, predominantly \<5 mm, none \>1 cm; Stage 2 = 10-25 polyps with ≥1 polyp \>1 cm, all amenable to complete removal; Stage 3 = \>25 polyps amenable to complete removal, an incompletely removed sessile polyp, or high-grade dysplasia; Stage 4 = high-grade dysplasia in an incompletely removed lesion and/or invasive colorectal cancer. Change from baseline was calculated as the difference in stage between baseline and post-treatment assessment.

    Time frame: Following patients out to 6 and 12 months.

  3. Clinical Effect of eRapa on Spigelman Stage Score.

    The Spigelman Staging System is a validated clinical scoring system used to assess the severity of duodenal polyposis in patients with Familial Adenomatous Polyposis (FAP). The score is based on four components evaluated during upper endoscopy: number of duodenal adenomas, size of the largest adenoma, histology, and degree of dysplasia. Points are assigned to each component and summed to generate a total score ranging from 0 to 12. The overall stage is classified as Stage 0 (0 points), Stage I (1-4 points), Stage II (5-6 points), Stage III (7-8 points), or Stage IV (9-12 points), with higher stages indicating more severe duodenal disease. The measure consists of a single overall stage and does not include subscale scores. Reported values represent absolute Spigelman stage at each assessment timepoint. Change from baseline was calculated as the difference in stage between baseline and post-treatment assessment.

    Time frame: Following patients out to 6 and 12 months.

  4. Percent Change From Baseline in Duodenal Polyp Burden at Months 6 and 12

    Duodenal polyp burden was assessed by gastroduodenoscopy at baseline and at Months 6 (180 days) and 12 (360 days), performed by the same gastroenterologist whenever possible. Polyps measuring ≥3 mm were counted, and the diameter of each eligible duodenal polyp was measured. Duodenal polyp burden was defined as the sum of the diameters of all eligible duodenal polyps. Polyps removed at the baseline endoscopy were excluded from the baseline polyp burden calculation to avoid attributing reductions due to polypectomy to study treatment. Percent change from baseline was calculated separately for the Month 6 and Month 12 assessments as: \[(follow-up polyp burden - adjusted baseline polyp burden) ÷ adjusted baseline polyp burden\] × 100.

    Time frame: Following patients out to 6 and 12 months.

  5. Determine the Effect of Food on eRapa Absorption cMax

    Cmax pharmacokinetic parameters to assess the effect of food on the bioavailability of the anticipated RP2D

    Time frame: 2 months

  6. Determine the Effect of Food on eRapa Absorption AUC

    AUC₀-∞ Pharmakinetic parameters to assess the effect of food on eRapa absorption

    Time frame: 2 months

  7. Sum of Diameters of Eligible Colorectal Polyps at Baseline

    Colorectal polyp burden was assessed by gastroduodenoscopy at baseline. Polyps measuring ≥3 mm were counted, and the diameter of each eligible colorectal polyp was measured. Baseline colorectal polyp burden was defined as the sum of the diameters of all eligible colorectal polyps. Polyps removed at the baseline endoscopy were excluded from the baseline polyp burden calculation.

    Time frame: baseline

  8. Sum of Diameters of Eligible Duodenal Polyps at Baseline

    Duodenal polyp burden was assessed by gastroduodenoscopy at baseline. Polyps measuring ≥3 mm were counted, and the diameter of each eligible duodenal polyp was measured. Baseline duodenal polyp burden was defined as the sum of the diameters of all eligible duodenal polyps. Polyps removed at the baseline endoscopy were excluded from the baseline polyp burden calculation.

    Time frame: baseline

07

Results

Posted Oct 22, 2026

Participant flow

Participants were recruited and screened for eligibility at the study site(s). Eligible participants were enrolled into the dose-escalation phase (Part 1) and assigned sequentially to Cohorts 1-3. Participants who completed Part 1 and continued to meet eligibility criteria were eligible to enroll in the food-effect crossover phase (Part 2), in which participants were randomized to one of two treatment sequences (Fed → Fasted or Fasted → Fed).

Dose Escalation
Participant flow — Dose Escalation
MilestonePart 1, Cohort 1Part 1, Cohort 2Part 1, Cohort 3Part 2 Food Effect Crossover: Fed→Fasted SequencePart 2: Food Effect Crossover - Fasted→Fed Sequence
Started10101000
Completed108800
Not completed02200
Food Effect Crossover
Participant flow — Food Effect Crossover
MilestonePart 1, Cohort 1Part 1, Cohort 2Part 1, Cohort 3Part 2 Food Effect Crossover: Fed→Fasted SequencePart 2: Food Effect Crossover - Fasted→Fed Sequence
Started0001010
Completed00078
Not completed00032

Outcome measures

PrimaryPercent Change From Baseline in Colorectal Polyp Burden at Month 6

Colorectal polyp burden was assessed by colonoscopy at baseline and Month 6 (180 days), performed by the same gastroenterologist whenever possible. Polyps measuring ≥3 mm were counted, and the diameter of each eligible polyp was measured. Colorectal polyp burden was defined as the sum of the diameters of all eligible colorectal polyps. Polyps removed at the baseline endoscopy were excluded from the baseline polyp burden calculation to avoid attributing reductions due to polypectomy to study treatment. Percent change from baseline was calculated as: (Month6polypburden-adjustedbaselinepolypburden)÷adjustedbaselinepolypburden × 100.

Time frame:
6 months
Reported as:
Mean · percent change polyp burden
Percent Change From Baseline in Colorectal Polyp Burden at Month 6
percent change polyp burdenPart 1, Cohort 1Part 1, Cohort 2Part 1, Cohort 3
Percent Change From Baseline in Colorectal Polyp Burden at Month 626.40 ± 170.474-10.84 ± 62.041269.79 ± 668.411
SecondaryPercent Change From Baseline in Colorectal Polyp Burden at Month 12

Colorectal polyp burden was assessed by colonoscopy at baseline and Month 12 (360 days), performed by the same gastroenterologist whenever possible. Polyps measuring ≥3 mm were counted, and the diameter of each eligible polyp was measured. Colorectal polyp burden was defined as the sum of the diameters of all eligible colorectal polyps. Polyps removed at the baseline endoscopy were excluded from the baseline polyp burden calculation to avoid attributing reductions due to polypectomy to study treatment. Percent change from baseline was calculated as: \[(Month 12 polyp burden - adjusted baseline polyp burden) ÷ adjusted baseline polyp burden\] × 100.

Time frame:
12 months.
Reported as:
Mean · Percent Change Polyp Burden
Percent Change From Baseline in Colorectal Polyp Burden at Month 12
Percent Change Polyp BurdenPart 1, Cohort 1Part 1, Cohort 2Part 1, Cohort 3
Percent Change From Baseline in Colorectal Polyp Burden at Month 1272.55 ± 157.675-1.24 ± 81.323679.64 ± 1551.148
SecondaryClinical Effect of eRapa on International Society for Gastrointestinal Hereditary Tumors (InSiGHT) Stage.

The International Society for Gastrointestinal Hereditary Tumours (InSiGHT) Familial Adenomatous Polyposis (FAP) Staging System is a validated clinical scoring system used to assess the severity of polyposis in patients with FAP. Staging is based on polyp number, size, endoscopic resectability, and the presence of advanced pathology. The scale consists of a single overall stage (0-4) and does not include subscale scores: Stage 0 = 0-10 polyps, all \<5 mm; Stage 1 = 10-25 polyps, predominantly \<5 mm, none \>1 cm; Stage 2 = 10-25 polyps with ≥1 polyp \>1 cm, all amenable to complete removal; Stage 3 = \>25 polyps amenable to complete removal, an incompletely removed sessile polyp, or high-grade dysplasia; Stage 4 = high-grade dysplasia in an incompletely removed lesion and/or invasive colorectal cancer. Change from baseline was calculated as the difference in stage between baseline and post-treatment assessment.

Time frame:
Following patients out to 6 and 12 months.
Reported as:
Mean · units on a scale
Clinical Effect of eRapa on International Society for Gastrointestinal Hereditary Tumors (InSiGHT) Stage.
units on a scalePart 1, Cohort 1Part 1, Cohort 2Part 1, Cohort 3
6 month analysis1.9 ± 1.11.9 ± 1.291.7 ± 1.41
12 month analysis2.0 ± 1.051.8 ± 1.31.7 ± 1.42
Baseline2.5 ± 0.852.3 ± 0.951.8 ± 1.03
SecondaryClinical Effect of eRapa on Spigelman Stage Score.

The Spigelman Staging System is a validated clinical scoring system used to assess the severity of duodenal polyposis in patients with Familial Adenomatous Polyposis (FAP). The score is based on four components evaluated during upper endoscopy: number of duodenal adenomas, size of the largest adenoma, histology, and degree of dysplasia. Points are assigned to each component and summed to generate a total score ranging from 0 to 12. The overall stage is classified as Stage 0 (0 points), Stage I (1-4 points), Stage II (5-6 points), Stage III (7-8 points), or Stage IV (9-12 points), with higher stages indicating more severe duodenal disease. The measure consists of a single overall stage and does not include subscale scores. Reported values represent absolute Spigelman stage at each assessment timepoint. Change from baseline was calculated as the difference in stage between baseline and post-treatment assessment.

Time frame:
Following patients out to 6 and 12 months.
Reported as:
Mean · score on a scale
Clinical Effect of eRapa on Spigelman Stage Score.
score on a scalePart 1, Cohort 1Part 1, Cohort 2Part 1, Cohort 3
6 Month analysis2.1 ± 1.052.0 ± 1.071.8 ± 0.84
12 month analysis2.0 ± 0.872.1 ± 0.91.6 ± 0.98
Baseline2.2 ± 0.832.1 ± 1.171.3 ± 1.12
SecondaryPercent Change From Baseline in Duodenal Polyp Burden at Months 6 and 12

Duodenal polyp burden was assessed by gastroduodenoscopy at baseline and at Months 6 (180 days) and 12 (360 days), performed by the same gastroenterologist whenever possible. Polyps measuring ≥3 mm were counted, and the diameter of each eligible duodenal polyp was measured. Duodenal polyp burden was defined as the sum of the diameters of all eligible duodenal polyps. Polyps removed at the baseline endoscopy were excluded from the baseline polyp burden calculation to avoid attributing reductions due to polypectomy to study treatment. Percent change from baseline was calculated separately for the Month 6 and Month 12 assessments as: \[(follow-up polyp burden - adjusted baseline polyp burden) ÷ adjusted baseline polyp burden\] × 100.

Time frame:
Following patients out to 6 and 12 months.
Reported as:
Mean · Percent Change Polyp Burden
Percent Change From Baseline in Duodenal Polyp Burden at Months 6 and 12
Percent Change Polyp BurdenPart 1, Cohort 1Part 1, Cohort 2Part 1, Cohort 3
6 month analysis-34.82 ± 41.71232.64 ± 115.920103.38 ± 122.222
12 month analysis20.90 ± 80.67735.77 ± 70.926131.52 ± 200.868
SecondaryDetermine the Effect of Food on eRapa Absorption cMax

Cmax pharmacokinetic parameters to assess the effect of food on the bioavailability of the anticipated RP2D

Time frame:
2 months
Reported as:
Geometric mean · ng/ml
Determine the Effect of Food on eRapa Absorption cMax
ng/mlFood-Effect Crossover, Part 2 eRapa RPSD Pharmacokinetics Under Fed ConditionsFood-Effect Crossover, Part 2: Rapa RP2D Pharmacokinetics Under Fasted Conditions
Determine the Effect of Food on eRapa Absorption cMax1.96 ± 60.6673.58 ± 62.606
SecondaryDetermine the Effect of Food on eRapa Absorption AUC

AUC₀-∞ Pharmakinetic parameters to assess the effect of food on eRapa absorption

Time frame:
2 months
Reported as:
Geometric mean · ng*min/mL
Determine the Effect of Food on eRapa Absorption AUC
ng*min/mLFood-Effect Crossover, Part 2 eRapa RPSD Pharmacokinetics Under Fed ConditionsFood-Effect Crossover, Part 2: Rapa RP2D Pharmacokinetics Under Fasted Conditions
Determine the Effect of Food on eRapa Absorption AUC1479.59 ± 31.8272564.92 ± 47.812
SecondarySum of Diameters of Eligible Colorectal Polyps at Baseline

Colorectal polyp burden was assessed by gastroduodenoscopy at baseline. Polyps measuring ≥3 mm were counted, and the diameter of each eligible colorectal polyp was measured. Baseline colorectal polyp burden was defined as the sum of the diameters of all eligible colorectal polyps. Polyps removed at the baseline endoscopy were excluded from the baseline polyp burden calculation.

Time frame:
baseline
Reported as:
Mean · mm
Sum of Diameters of Eligible Colorectal Polyps at Baseline
mmPart 1, Cohort 1Part 1, Cohort 2Part 1, Cohort 3
Sum of Diameters of Eligible Colorectal Polyps at Baseline325.9 ± 370.54224.8 ± 244.9175.1 ± 91.81
SecondarySum of Diameters of Eligible Duodenal Polyps at Baseline

Duodenal polyp burden was assessed by gastroduodenoscopy at baseline. Polyps measuring ≥3 mm were counted, and the diameter of each eligible duodenal polyp was measured. Baseline duodenal polyp burden was defined as the sum of the diameters of all eligible duodenal polyps. Polyps removed at the baseline endoscopy were excluded from the baseline polyp burden calculation.

Time frame:
baseline
Reported as:
Mean · mm
Sum of Diameters of Eligible Duodenal Polyps at Baseline
mmPart 1, Cohort 1Part 1, Cohort 2Part 1, Cohort 3
Sum of Diameters of Eligible Duodenal Polyps at Baseline75.30 ± 127.5053.80 ± 71.5024.3 ± 28.96

Adverse events

Collected over 12 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1, Cohort 10/10 (0%)5/10 (50%)9/10 (90%)
Part 1, Cohort 20/10 (0%)1/10 (10%)7/10 (70%)
Part 1, Cohort 30/10 (0%)2/10 (20%)10/10 (100%)
Food-Effect Crossover, Part 2 eRapa RPSD Pharmacokinetics Under Fed Conditions0/7 (0%)1/7 (14.3%)4/7 (57.1%)
Food-Effect Crossover, Part 2 eRapa RPSD Pharmacokinetics Under Fasted Conditions0/8 (0%)1/8 (12.5%)4/8 (50%)
Most frequent serious events
Most frequent serious events
EventPart 1, Cohort 1Part 1, Cohort 2Part 1, Cohort 3Food-Effect Crossover, Part 2 eRapa RPSD Pharmacokinetics Under Fed ConditionsFood-Effect Crossover, Part 2 eRapa RPSD Pharmacokinetics Under Fasted Conditions
Small intestinal obstuctionGastrointestinal disorders2/100/101/101/71/8
PancreatitisGastrointestinal disorders1/100/101/100/70/8
Rectal haemorrhageGastrointestinal disorders1/100/100/100/70/8
BradycardiaCardiac disorders0/100/101/100/70/8
Bile duct stoneHepatobiliary disorders0/101/100/100/70/8
Gastroenteritis rotavirusInfections and infestations1/100/100/100/70/8
Most frequent other events
Showing 10 of 29
Most frequent other events
EventPart 1, Cohort 1Part 1, Cohort 2Part 1, Cohort 3Food-Effect Crossover, Part 2 eRapa RPSD Pharmacokinetics Under Fed ConditionsFood-Effect Crossover, Part 2 eRapa RPSD Pharmacokinetics Under Fasted Conditions
DiarrhoeaGastrointestinal disorders3/102/103/101/71/8
StomatitisGastrointestinal disorders1/100/103/100/70/8
NauseaGastrointestinal disorders2/101/101/100/70/8
Rectal haemorrhageGastrointestinal disorders2/101/100/100/70/8
Small intestinal obstructionGastrointestinal disorders2/100/101/101/71/8
VomitingGastrointestinal disorders0/100/102/100/70/8
HypoglycaemiaMetabolism and nutrition disorders2/100/100/100/70/8
HypokalaemiaMetabolism and nutrition disorders1/100/102/100/70/8
ConstipationGastrointestinal disorders1/100/101/101/70/8
Dry mouthGastrointestinal disorders1/100/101/101/70/8

Baseline characteristics

The food effect participants were selected from Cohorts 1, 2 or 3 - it was a sub-study so participants are not counted twice

Age, Categorical
Age, Categorical(Participants)Part 1, Cohort 1Part 1, Cohort 2Part 1, Cohort 3Total
<=18 years0000
Between 18 and 65 years10101030
>=65 years0000
Age, Continuous
Age, Continuous(years)Part 1, Cohort 1Part 1, Cohort 2Part 1, Cohort 3Total
Mean45 ± 12.0943.9 ± 8.7148.1 ± 12.9446.75 ± 11.01
Sex: Female, Male
Sex: Female, Male(Participants)Part 1, Cohort 1Part 1, Cohort 2Part 1, Cohort 3Total
Female26715
Male84315
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1, Cohort 1Part 1, Cohort 2Part 1, Cohort 3Total
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White10101030
More than one race0000
Unknown or Not Reported0000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1, Cohort 1Part 1, Cohort 2Part 1, Cohort 3Total
Hispanic or Latino1113
Not Hispanic or Latino99927
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)Part 1, Cohort 1Part 1, Cohort 2Part 1, Cohort 3Total
United States10101030
Polyp Burden
Polyp Burden(Number of polyps)Part 1, Cohort 1Part 1, Cohort 2Part 1, Cohort 3Total
Mean325.9 ± 370.54224.8 ± 244.9175.1 ± 95.81208.6 ± 273.54
08

Study locations

4 sites
  • Michigan Medicine
    Ann Arbor, Michigan 48109, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Ohio State University
    Columbus, Ohio 43210, United States
  • UT Health
    San Antonio, Texas 78229, United States
09

References and documents

Publications

  • Stone JK, Mehta NA, Singh H, El-Matary W, Bernstein CN. Endoscopic and chemopreventive management of familial adenomatous polyposis syndrome. Fam Cancer. 2023 Oct;22(4):413-422. doi: 10.1007/s10689-023-00334-3. Epub 2023 Apr 29. PubMed 37119510 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jan 2021 to primary completion in Dec 2024, 46 months.

Results were first posted in Oct 2026, 1 year 10 months after primary completion.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: primary completion Mar 2025 → Dec 2024 and completion Mar 2025 → May 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2020
First posted
Jan 18, 2020
StartActual
Jan 18, 2021
Primary completionActual
Dec 11, 2024was Mar 2025
CompletionActual
May 22, 2025was Mar 2025
Results first posted
Oct 22, 2026
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 22, 2026
Results
Results posted
posted Oct 22, 2026
Primary completion
Mar 2025→Dec 11, 2024 (actual)
Oct 22, 2026
Study completion
Mar 2025→May 22, 2025 (actual)
Oct 22, 2026
Primary outcomes
1 added, 3 removed
What changed in the outcomes
  • AddedPercent Change From Baseline in Colorectal Polyp Burden at Month 6Time frame: 6 months
  • RemovedFrequency and severity of adverse events associated with low dose eRapa in FAP patientsTime frame: All adverse events with start dates occurring any time after informed consent is obtained until 7 days (for non-serious adverse events) or 30 days (for serious adverse events) after the last day of study participation will be recorded.
  • RemovedDetermine the Recommended Phase 2 Dose (RP2D)Time frame: After informed consent is obtained up to 30 days after the last day of study participation.
  • RemovedEfficacy of eRapa in delaying polyp progression in patients with FAP as measured by change in polyp burden over time.Time frame: Time for each patient is baseline to 6 months.
Oct 22, 2026
Documents
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 37119510 ↗
Oct 22, 2026
Secondary outcomes
3 edited, 5 added, 3 removed
What changed in the outcomes
  • EditedClinical effectEffect of eRapa on polyp burdenInternational Society for Gastrointestinal Hereditary Tumors (InSiGHT) Stage.Time frame: Following patients out to 12 months. → Following patients out to 6 and 12 months.
  • EditedClinical effectEffect of eRapa on International Society for Gastrointestinal Hereditary TumorsSpigelman Stage Score.Time frame: Following patients out to 6 and 12 months.
  • EditedDetermine the effectEffect of foodFood on eRapa absorptionAbsorption cMaxTime frame: 2 months
  • AddedPercent Change From Baseline in Colorectal Polyp Burden at Month 12Time frame: 12 months.
  • AddedPercent Change From Baseline in Duodenal Polyp Burden at Months 6 and 12Time frame: Following patients out to 6 and 12 months.
  • AddedDetermine the Effect of Food on eRapa Absorption AUCTime frame: 2 months
  • AddedSum of Diameters of Eligible Colorectal Polyps at BaselineTime frame: baseline
  • AddedSum of Diameters of Eligible Duodenal Polyps at BaselineTime frame: baseline
  • RemovedClinical effect of eRapa on Spigelman Stage Score.Time frame: Following patients out to 6 and 12 months.
  • RemovedClinical effect of eRapa on duodenal polyp number and burden.Time frame: Following patients out to 6 and 12 months.
  • Removedother outcomeExplore correlation between immune markers influenced by mTOR inhibition and clinical outcomesTime frame: Following patients out to 12 months.
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Active, not recruiting→Completed
    Results posted
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 37119510 ↗
    Primary completion Mar 2025→Dec 11, 2024 (now actual)
    Study completion Mar 2025→May 22, 2025 (now actual)
    Primary outcomes 1 added, 3 removed
    What changed in the outcomes
    • AddedPercent Change From Baseline in Colorectal Polyp Burden at Month 6Time frame: 6 months
    • RemovedFrequency and severity of adverse events associated with low dose eRapa in FAP patientsTime frame: All adverse events with start dates occurring any time after informed consent is obtained until 7 days (for non-serious adverse events) or 30 days (for serious adverse events) after the last day of study participation will be recorded.
    • RemovedDetermine the Recommended Phase 2 Dose (RP2D)Time frame: After informed consent is obtained up to 30 days after the last day of study participation.
    • RemovedEfficacy of eRapa in delaying polyp progression in patients with FAP as measured by change in polyp burden over time.Time frame: Time for each patient is baseline to 6 months.
    Secondary outcomes 3 edited, 5 added, 3 removed
    What changed in the outcomes
    • EditedClinical effectEffect of eRapa on polyp burdenInternational Society for Gastrointestinal Hereditary Tumors (InSiGHT) Stage.Time frame: Following patients out to 12 months. → Following patients out to 6 and 12 months.
    • EditedClinical effectEffect of eRapa on International Society for Gastrointestinal Hereditary TumorsSpigelman Stage Score.Time frame: Following patients out to 6 and 12 months.
    • EditedDetermine the effectEffect of foodFood on eRapa absorptionAbsorption cMaxTime frame: 2 months
    • AddedPercent Change From Baseline in Colorectal Polyp Burden at Month 12Time frame: 12 months.
    • AddedPercent Change From Baseline in Duodenal Polyp Burden at Months 6 and 12Time frame: Following patients out to 6 and 12 months.
    • AddedDetermine the Effect of Food on eRapa Absorption AUCTime frame: 2 months
    • AddedSum of Diameters of Eligible Colorectal Polyps at BaselineTime frame: baseline
    • AddedSum of Diameters of Eligible Duodenal Polyps at BaselineTime frame: baseline
    • RemovedClinical effect of eRapa on Spigelman Stage Score.Time frame: Following patients out to 6 and 12 months.
    • RemovedClinical effect of eRapa on duodenal polyp number and burden.Time frame: Following patients out to 6 and 12 months.
    • Removedother outcomeExplore correlation between immune markers influenced by mTOR inhibition and clinical outcomesTime frame: Following patients out to 12 months.
    + 6 other changes: identifiers, verification date, registry dates, oversight details, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04230499
Lead sponsor
Rapamycin Holdings Inc.
Collaborators
Cancer Insight, LLC, Biodexa Pharmaceuticals
Responsible party
Sponsor
First posted
Jan 18, 2020
Start date
Jan 18, 2021
Primary completion
Dec 11, 2024
Completion
May 22, 2025
Results posted
Oct 22, 2026
Last update
Oct 22, 2026

Study contacts

Gary Shangold, MD
study director · Sponsor CMO

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Encapsulated Rapamycin

Start the discussion